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The results of recatheterization were assessed in a select group of 
95 patients enrolled in the Mansfield Scientific Aortic Valvulo-
plasty Registry to determine whether any procedural or patient-
related variables at baseline predicted either initial immediate or 
follow-up (6.2 ± 3.3 months) results. At the follow-up catheter-
ization, 39 (41 %) of the patients were in improved condition and 
56 patients (59%) had recurrence of symptoms, allowing for 
analysis of the effect of the procedure in two symptomatic patient 
subsets. 
In the total group the aortic valve area increased initially from 
0.56 ± 0.16 to 0.87 ± 0.27 cm2 but partial return to the baseline 
valve area was evident at follow-up (0.63 ± 0.25 cm2). Similarly, 
the mean aortic gradient initially decreased from 72 ± 30 to 35 ± 
16 mm Hg but then increased to 55 ± 25 mm Hg at follow-up. 
Neither the initial nor the late hemodynamic results appeared 
affected by any definable procedural variable at the time of 
valvuloplasty, including the maximal diameter of balloons, num-
ber of balloons simultaneously used, mean inflation time or total 
number of inflations. 
Percutaneous balloon aortic valvuloplasty has emerged as a 
therapeutic option in selected patients with severe aortic 
stenosis who are poor candidates for surgery (1-5). How-
ever, clinical studies (2,6,7) have revealed that evidence for 
restenosis, with or without return of clinical symptoms, 
occurs frequently. The acute relief of aortic obstruction 
observed using balloon catheter techniques appears to result 
from fracture of valvular calcium, tearing of commissural 
scar and perhaps stretching of the cusps or the aortic anulus 
(8-13). In the early days after the procedure, partial return of 
a pressure gradient occurs because of both remodeling of the 
aortic valve and an improvement in stroke volume (14,15). 
Restenosis may be an inevitable consequence at some point, 
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Such technical concerns also did not seem to affect short- or 
long-term outcome. Similarly, no baseline hemodynamic variable 
clearly separated those who became increasingly symptomatic 
from those whose condition was improved at the 6 month interval. 
At recatheterization, a reduction in the aortic valve area toward 
baseline was observed in 24 (62 % ) of the 39 improved patients and 
in 45 (80%) of the 56 who were symptomatic. At follow-up the less 
symptomatic group did have a greater aortic valve area 
(0.70 ± 0.32 versus 0.58 ± 0.18 cm2; p = 0.02) and a slightly 
higher ejection fraction (59 ± 19% versus 48 ± 20%; P = 0.07) 
than the symptomatic group. 
Thus, in this select group of patients, differences in procedural 
techniques at the time of aortic valvuloplasty did not appear to 
influence the return toward the baseline aortic valve gradient at 
follow-up. Fewer symptoms at follow-up were observed in those 
patients achieving the greatest aortic valve area after the proce-
dure and in those with maintenance of left ventricular contractile 
performance. 
(J Am Coli CardioI1991;17:1188-95) 
after the procedure, although the mechanism of restenosis 
has yet to be well defined and its definition is controversial 
especially in light of the vagaries in the measurement of 
aortic valve area. It remains unclear, for example, which 
factors, such as valve architecture (12), underlying ventric-
ular function (16-18) or variations in the procedure itself 
(19-23), might be most important in delaying restenosis or 
the return of symptoms. Preliminary studies (3) have sug-
gested that the final aortic valve area probably best predicts 
early restenosis, and it has been advocated that a final aortic 
valve area> 1.0 cm2 after valvuloplasty should always be 
sought. 
To date, follow-up data in patients after aortic valvulo-
plasty have primarily used noninvasive methods, such as 
Doppler echocardiography, to estimate the severity of the 
valvular gradient or to measure aortic valve area. Although 
Doppler gradients correlate reasonably well with invasive 
measures, substantial standard errors for the measurement 
of the mean aortic gradient and of the aortic valve area using 
the continuity equation have been described (24). For these 
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reasons, follow-up invasive data are important to allow for 
comparison of serial hemodynamic changes with use of 
similar techniques. 
Analysis of data in the Mansfield Scientific Aortic Valvu-
loplasty Registry from December I, 1986 to September I, 
1988 reveals that 95 patients underwent repeat catheteriza-
tion after aortic valvuloplasty. This time interval is greater 
than that reported elsewhere in this seminar. Both patient 
characteristics and details of the technique at the time of the 
initial procedure were available for review. This presenta-
tion is an assessment of the effect of these variables on the 
subsequent follow-up invasive hemodynamic outcome In 
these patients. 
Methods 
The Mansfield Scientific Aortic Valvuloplasty Registry. 
The Registry is a corporate-sponsored data base established 
through Mansfield Scientific and conducted under Food and 
Drug Administration-approved investigation device exemp-
tion. Clinical sites were required to complete a questionnaire 
regarding a series of procedural events, hemodynamic re-
sults and complications in all patients undergoing aortic 
valvuloplasty using balloon valvuloplasty catheters designed 
by the parent company. In addition to clinical follow-up, 
data from repeat catheterization were also sought. 
During this time, 785 patients were enrolled in the Reg-
istry. At the time of this report, 525 patients were both alive 
and eligible for a 6 month follow-up catheterization. Fol-
low-up catheterization was not a routine requirement; there-
fore, many patients underwent recatheterization because of 
recurrence of symptoms. In some centers recatheterization 
was incorporated into an institutionally approved protocol 
for the evaluation of the aortic valvuloplasty procedure. 
Therefore, the Registry included a mixed group of patients 
who had undergone repeat catheterization. Of the 525 eligi-
ble patients, 95 (18%) underwent recatheterization and these 
patients form the basis of this report. 
An aortic valvuloplasty data base form allowed recording 
of information regarding the valvuloplasty procedure, as 
well as pertinent hemodynamic data and clinical symptoms. 
The procedural data base included the number of balloons 
used, the maximal diameter of each balloon, the balloon 
length, the number of inflations, the duration of each infla-
tion and information on whether balloon rupture occurred 
and whether any complications ensued. 
A baseline data base was also derived regarding the 
symptomatic status of each patient. This included documen-
tation of fatigue, shortness of breath, angina, syncope, 
congestive heart failure class (New York Heart Association) 
and angina class (Canadian Cardiovascular Society). The 
overall clinical status was also recorded as stable, improving 
or worsening. 
Recatheterization data were tabulated in a manner sim-
ilar to that recorded at baseline. Recatheterization was 
performed at an average of 6.2 ± 3.3 months after the 
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baseline procedure. At recatheterization 42 patients (44%) 
underwent repeat aortic valvuloplasty. Another five patients 
had repeat valvuloplasty during the same readmission. Thir-
teen patients (14%) underwent aortic valve replacement 
during the follow-up hospital admission and seven patients 
(7%) died during that hospital stay. 
Patient characteristics. Table 1 outlines pertinent base-
line clinical descriptors before valvuloplasty in the 95 pa-
tients who underwent recatheterization and contrasts them 
with descriptors in the subgroup of patients who did not 
undergo repeat catheterization. The two groups had similar 
baseline characteristics except for slightly more coronary 
artery disease and slightly less congestive heart failure in the 
study cohort. At 6 months more symptoms were present in 
the recatheterization group. Because 30% of patients died 
before they were eligible for recatheterization, the signifi-
cance of this observation is unclear except that it confirms 
the view that many patients were restudied because symp-
toms were present. Because all descriptors were not re-
corded for all data items, Table 1 includes the actual number 
of patients from whom the data were derived for each 
variable. Overall, the patient group is elderly with mild to 
moderate coronary artery disease, moderately well pre-
served ventricular function and a modest degree of aortic 
regurgitation. 
Table 2 outlines the symptomatic status of the 95 patients 
at baseline and at the time of the repeat study. Symptomatic 
improvement at recatheterization was evident in regard to 
heart failure classification, syncope and angina. However, 
the overall number of patients with any symptom of fatigue 
or dyspnea was unchanged. At the time of recatheterization, 
the condition of 39 (41 %) was considered improved, whereas 
56 (59%) had either similar or worse symptoms compared 
with baseline. 
Statistical analysis. Data were expressed as the mean 
values ± SD or as mean values and the 95% confidence 
limits for the mean. Statistical analysis between groups was 
performed using either a paired or unpaired t test for 
continuous data and Fisher's exact test for dichotomous 
variables. A p value < 0.05 was considered significant. 
Results 
Initial and follow-up hemodynamic changes observed. 
Table 3 outlines the initial hemodynamic changes observed 
in the patients at the time of their original aortic valvulo-
plasty procedure and contrasts the data with data observed 
at follow-up catheterization. Ejection fraction values ob-
tained immediately after the procedure were not recorded on 
the data sheets and were not available for review. 
Figure 1 displays the immediate effects of aortic valvulo-
plasty on the aortic valve area and contrasts these initial 
measurements with values observed at follow-up catheter-
ization. It is obvious that a return toward the baseline 
gradient and aortic valve area was common. When patients 
with fewer symptoms were compared with those whose 
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Table 1. Comparison of Patients Undergoing Recatheterization With Patients Who Had No Recatheterization Performed 
Recatheterization No Recatheterization 
No.(%) n No(%) n p Value 
Baseline characteristic 
Male(%) 47 (49%) 95 310 (45%) 690 NS 
Age (yr) 75 ± 10 95 78 ± 5 690 <0.001 
CHF 51 (54%) 95 296 (68%) 435 <0.01 
NYHA I or II 23 (24%) 91 84 (19%) 444 NS 
NYHA III or IV 68 (71%) 91 360 (81%) 444 NS 
Fatigue 56 (59%) 95 317 (71%) 445 <0.05 
Dyspnea 83 (87%) 95 431 (91%) 472 NS 
Angina 53 (56%) 95 239 (51%) 469 NS 
Syncope 22 (23%) 95 113 (25%) 455 NS 
Aortic regurgitation 
o to mild 57 (85%) 67 380 (88%) 433 NS 
Moderate to severe 10 (15%) 67 53 (12%) 433 NS 
CAD 
None or IVD 70 (74%) 89 424 (76%) 560 NS 
2VD or 3VD 19 (26%) 89 136 (24%) 560 NS 
Prevalvuloplasty Hemodynamics 
AVA (cm2) 0.56 ± 0.16 95 0.50 ± 0.18 684 <0.01 
Peak to peak aortic gradient (mm Hg) 72 ± 30 95 60 ± 23 690 <0.001 
L VEDP (mm Hg) 19 ± 11 95 19 ± 14 670 NS 
LVEF(%) 49 ± 20 65 49 ± 19 316 NS 
Postvalvuloplasty Hemodynamics 
AVA (cm2) 0.87 ± 0.27 95 0.82 ± OJI 673 NS 
Mean aortic pressure gradient (mm Hg) 35 ± 16 95 30 ± 13 678 <0.001 
Follow-up symptoms 
Mean FlU time (mo.) 6.2 95 6.7 443 NS 
CHF 47 (49%) 95 102 (34%) 298 <0.01 
NYHA I or II 35 (37%) 95 241 (62%) 386 <0.0005 
NYHA III or IV 54 (57%) 95 145 (38%) 386 <0.005 
Fatigue 58 (61%) 95 147 (49%) 303 <0.05 
Dyspnea 68 (71%) 95 185 (60%) 307 <0.05 
Angina 31 (33%) 95 63 (21%) 303 <0.025 
Syncope II (12%) 95 20 (7%) 293 NS 
Improved (%) 39 (41%) 95 21\ (65%) 325 <0.0005 
The baseline characteristics, hemodynamic values before and immediately after valvuloplasty and the symptoms at the follow-up (FlU) interval are displayed 
for those who had, compared with those who had not, undergone recatheterization. There are no differences noted in any baseline characteristic except for a slight 
increase in fatigue and congestive heart failure (CHF) in the subsets not undergoing recatheterization. No hemodynamic measurement differed between the two 
groups. At follow-up the recatheterization group of patients had more symptoms in all categories and were generally less improved. This suggests that in the 
majority of patients recatheterization was performed because of symptoms. AVA = aortic valve area; CAD = coronary artery disease; LVEDP = left ventricular 
end-diastolic pressure; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association; VD = vessel disease. 
symptoms had returned to baseline severity, there was no 
difference in any measurable baseline hemodynamic varia-
bles. Similarly, when the immediate results of the valvulo-
plasty were assessed, there was no acute postprocedural 
hemodynamic variable seen more commonly in the patients 
with improved status than in those with recurrent symptoms 
(Table 4). 
At follow-up catheterization, many patients with im-
provement demonstrated evidence for a return of the valve 
gradient. The follow-up aortic valve area was larger in 
patients who were clinically improved at 6 months. These 
patients also had a higher ejection fraction and had experi-
enced a greater change in the ejection fraction from baseline 
(from 50 ± 21% to 59 ± 19%) compared with that in patients 
whose symptoms had worsened or returned to baseline 
Table 2. Symptomatic Status of Patients 
Undergoing Recatheterization 
At At 6 Month 
Baseline Recatheterization 
Congestive heart failure 51 (54%) 47 (49%) 
Fatigue 56 (59%) 58 (61%) 
Dyspnea 83 (87%) 68 (71%) 
NYHA I or II 23 (24%) 35 (37%) 
NYHA III or IV 68 (71%) 54 (57%) 
Angina 53 (53%) 31 (33%) 
Syncope 22 (23%) II (12%) 
p Value 
NS 
NS 
NS 
<0.05 
<0.05 
<0.05 
<0.05 
The change in symptomatic status in patients undergoing recatheterization 
is redisplayed from Table I. At recatheterization a reduction in anginal and 
syncopal symptoms was noted but there was no change in overall symptoms 
of heart failure in this select subset. More patients reported functional class I 
or II symptoms at follow-up than at baseline. 
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Table 3. Hemodynamic Data 
Baseline Immediately At Follow-Up 
Before BAV n After BAV n Catheterization n 
Aortic valve area (cm2) 0.56 :!: 0.18 95 0.87:!: 0.27 95 0.63 :!: 0.25 92 
Mean aortic gradient (mm Hg) 72 :!: 30 95 35 :!: 16 95 55:!: 25 94 
Peak to peak aortic gradient (mm Hg) 59:!: 21 95 32:!: 12 95 51 :!: 21 94 
LVEF(%) 49 :!: 20 65 NA 53 :!: 21 48 
L VEDP (mm Hg) 19:!: 11 95 16:!: 9 94 19:!: \0 95 
Baseline, immediate postvalvuloplasty and follow-up catheterization hemodynamic data in 95 patients. The initially improved hemodynamic values observed 
after balloon aortic valvuloplasty (BAV) have returned toward baseline in many patients. Abbreviations as in Table 1. 
levels. This finding may have clinical relevance because it 
appears symptoms may not recur despite evidence for a 
return toward baseline of the aortic valve area and gradient 
in some patients. 
Analysis of the procedural events and their impact on 
outcome. Several valvuloplasty technique variables were 
assessed to determine their relation to either the immediate 
or at 6 month follow-up catheterization outcome. Figure 2 
displays the effect of maximal balloon size (diameter) on the 
change in aorta valve area observed, the aortic valve area 
after the valvuloplasty procedure and the aortic valve area at 
recatheterization. Although there is a slight trend toward a 
larger resultant aortic valve area at recatheterization when 
larger balloons were used initially, in general the use of a larger 
balloon size did not seem to correlate with a better valve area 
at restudy. The number of patients for whom each balloon size 
Figure 1. Aortic valve area data in 95 patients. Left panel, the effect 
of balloon aortic valvuloplasty on the aortic valve area (A V A) 
immediately after the procedure. Note the upward shift in data 
points. Right panel, at recatheterization the aortic valve area has 
returned to baseline in many patients, although there are still more 
patients above the line of identity than below it. Individual dots often 
represent more than one patient. 
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was used is recorded at the bottom of the figure and it is 
important to note that the overwhelming majority of patients 
had either a single 20 mm balloon (63%) or a combination of 
balloons with a total summed diameter of 30 mm 01%). 
Because of the small number of patients with balloons of other 
sizes, it is difficult to discern the true effect of balloon size, 
other than that of the two most commonly used. 
The effect of the total number of balloon inflations on aortic 
valve area either immediately after the procedure or at recath-
eterization is shown in Figure 3. Again, the number of inflations 
appears to be unrelated to outcome; from two to six inflations 
were performed in most instances. On the assumption that the 
duration of each inflation may playa role, the hemodynamic 
status immediately after the procedure was assessed relative to 
inflation time. However, Figure 4 reveals no obvious relation 
between inflation time and aortic valve area. Similar findings 
were obtained for all hemodynamic variables. The majority of 
inflations lasted :0:;30 s. 
When these same technical variables were reassessed in 
the symptomatic subsets at 6 month follow-up study, no 
relation between any technical event and symptomatic out-
come was found. For instance, the largest diameter balloon 
or balloons in the patients with symptomatic improvement 
• 
• • • 
• • • 
• 
• n = 95 
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Table 4. Comparative Analysis of 39 Patients Symptomatically Improved Versus Those 56 With 
Similar or Worse Symptoms at the 6 Month Follow-up Catheterization 
Improved Compared Similar or Worse 
With Baseline Compared With Baseline 
(n = 39) (n = 56) P 
AVA (cm2) 
Baseline 0.57 ± 0.19 0.56 ± 0.18 0.71 
Acute post 0.91 ± 0.29 0.85 ± 0.24 0.32 
Follow-up 0.70 ± 0.32 0.58 ± 0.18 0.02 
Mean aortic gradient (mm Hg) 
Baseline 62 ± 21 57 ± 20 0.20 
Acute post 32 ± II 31 ± 18 0.47 
Follow-up 50 ± 20 52 ± 22 0.72 
Ejection fraction (%) 
Baseline 50 ± 21 47 ± 20 0.58 
Follow-up 59 ± 19 48 ± 20 0.07 
L VEDP (mm Hg) 
Baseline 21 ± 14 19 ± 12 0.42 
Acute post 16 ± 9 17 ± 8 0.76 
Follow-up 20 ± 11 18 ± 9 0.44 
At follow-up catheterization, the aortic valve area (A V A) was greater and the ejection fraction marginally higher 
in the group of patients with clinical improvement. No other identifiable variable was found that was more common 
in the improved subset. Abbreviations as in Table I. 
was 23 ± 6 mm versus 23 ± 6 mm in those with recurrent 
symptoms. Likewise, the average inflation time in the im-
proved group was 32 ± 19 s versus 29 ± 27 s in the group 
with recurrent symptoms (p = 0.56). 
Seventy patients (74%) had a single balloon procedure; 
the double balloon technique was used in 25 (26%). After the 
use of two balloons, the postvalvuloplasty area was 0.85 ± 
0.09 cm2 and the mean gradient was 38.5 ± 4.7 mm Hg. With 
use of a single balloon, the postprocedure aortic valve 
area was 0.88 ± 0.06 cm2 and the mean gradient was 29.6 ± 
2.7 mm Hg. However, this study was not designed to 
determine if the final aortic valve area is improved by the use 
of two balloons rather than one. Most patients underwent 
double balloon valvuloplasty when a single balloon proce-
dure was deemed inadequate. 
Discussion 
Aortic valvuloplasty results in initial improvement in the 
measured outflow gradient in most patients. However, the 
final aortic valve area that results is frequently less than that 
observed after aortic valve replacement (24). A return of the 
aortic valve area toward baseline is probably a certainty at 
some time after the procedure. 
Mechanisms of Restenosis 
Why restenosis occurs has not been completely eluci-
dated. Our study suggests that there is no measurable 
technique-related variable that predicts a rapid return of the 
aortic gradient by 6 months. It is more likely that restenosis 
is an inherent property of the architecture of the stenotic 
aortic valve itself. It may also be a function of the status of 
Figure 2. Effect of maximal balloon sizes. Maximal balloon diame-
ter was determined by using maximal balloon size derived from the 
maximal diameter of a single inflated balloon or the simple summation 
of the maximal diameter of two balloons. The relation between this 
diameter and the acute change (t;) in the aortic valve area (top panel), 
the acute post valvuloplasty aortic valve area (middle panel) and the 
aortic valve area at recatheterization (RECATH) (bottom panel) is 
shown. The number of patients at each maximal balloon diameter size 
is shown at the bottom of the figure. No clear pattern is evident, 
although most patients had either a 20 or 30 mm maximal diameter 
used. Data are expressed as mean ± 95% confidence interval. 
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Figure 3. Effect of number of inflations on aortic valve area. In the 
top panel the total number of inflations is displayed relative to the 
final aortic valve area (A V A) observed after the procedure; in the 
bottom panel the number of inflations is shown relative to the aortic 
valve area at recatheterization (RECATH). The number of patients 
represented is shown within each panel. No obvious relation is 
observed between the aortic valve area and the frequency of balloon 
inflation at the time of the valvuloplasty procedure. Data are 
expressed as mean values ± the 95% confidence interval. 
underlying left ventricular systolic performance. Patients 
with a low ejection fraction and a low aortic gradient can 
safely undergo aortic valvuloplasty (25,26), but baseline 
ventricular performance appears to profoundly affect even-
tual outcome (16,17). 
Role of symptomatic status. Fifty-nine percent of this 
patient group had recurrent symptoms at recatheterization 
and 41% were considered clinically improved from their 
baseline state. Despite symptomatic improvement, 69 pa-
tients (72%) had some reduction in the aortic valve area at 
recatheterization, including 62% of those with symptomatic 
Figure 4. Relation between average inflation time and the acute 
aortic valve area (AVA) achieved after the procedure. No relation is 
demonstrable between the two variables. 
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improvement and 80% with recurrent symptoms. The fol-
low-up ejection fraction in the improved subgroup was 
higher than those with recurrent symptoms (59 ± 19% versus 
48 ± 20%) despite a similar value at follow-up for the mean 
aortic gradient (50 ± 20 versus 52 ± 22 mm Hg) and only a 
slightly better aortic valve area (0.7 ± OJ versus 0.6 ± 
0.2 cm2). This finding is consistent with the view that 
symptomatic status may be more a function of ventricular 
performance than of the measured aortic valve area or 
gradient (27) . 
These data also reemphasize that valvular stenosis often 
precedes the onset of symptoms in patients with aortic 
stenosis. Patients undergoing aortic valvuloplasty should, 
therefore, be closely monitored for both return of the trans-
valvular gradient and further deterioration of left ventricular 
performance. The lack of recurrent symptoms did not indi-
cate that the aortic valve gradient had not increased. Con-
versely, 20% of patients with recurrent symptoms had little 
evidence for a return of the aortic gradient. Because symp-
toms alone did not consistently correlate with the status of 
the aortic outflow obstruction, the implication is that many 
patients suffer from the combined effects of impaired myo-
cardial function together with variable degrees of outflow 
obstruction. Symptomatic status appears particularly depen-
dent on diastolic ventricular performance characteristics 
after aortic valvuloplasty (27) and this may explain the 
apparent discrepancy observed in this study. 
Role of procedural factors. In addition, this study reveals 
that follow-up status in these patients is probably not pro-
cedure related. Despite the logical concept that aggressive 
efforts should be made to achieve the largest aortic valve 
area possible, the initial aortic valve area after valvuloplasty 
predicted neither symptomatic status nor aortic valve area at 
follow-up. Technical variables such as maximal balloon size, 
mean inflation time and the number of inflations seemed to 
bear no relation to either the initial or the follow-up hemo-
dynamic outcome. These data reemphasize that patient-
related variables are probably more important than proce-
dure-related variables in determining outcome. 
Valve architecture. The intrinsic valve architecture prob-
ably plays a key role in the success of the procedure. For 
example, it has been observed that a poorer outcome and 
more frequent complications may result when valvuloplasty 
is performed on bicuspid aortic valves (12,28,29) and better 
results may be observed when aortic valve stenosis is due to 
commissural fusion, as in rheumatic aortic stenosis (30). 
Most of the patients in this study probably had calcific aortic 
stenosis with a tricuspid leaflet and variable degrees of 
commissural fusion. Better characterization of the inherent 
valve structure in aortic stenosis might allow for better 
selection of patients who would benefit from aortic valvulo-
plasty. This has certainly been the case for percutaneous 
mitral valvotomy (31,32) and may be equally true for aortic 
valvuloplasty. A similar observation has been made regard-
ing the effect of valvuloplasty on congenital aortic valve 
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stenosis, where valve morphology is also a major issue in 
determining efficacy of the procedure (33). 
Role of ventricular function. The supporting role that 
underlying ventricular function plays in preventing return of 
the valve gradient and in lessening symptoms is of consid-
erable interest. In this study the symptomatic patients had 
little change in ejection fraction at 6 months, whereas the 
patients with clinical improvement had an increase from a 
mean of 50% to 59%. Ejection phase indexes, such as the 
ejection fraction, are obviously very sensitive to altered 
afterload (34) and hypertrophy alone leads to some degree of 
intrinsic myocardial dysfunction (35). Significant improve-
ment in ejection fraction has been observed in a few patients 
after aortic valvuloplasty (2) and dramatic improvement has 
occasionally been observed in patients after aortic valve 
replacement (36,37). Whether the improvement in left ven-
tricular systolic performance is related to inherent augmen-
tation in contractile function or simply to improved ejection 
dynamics is unclear (38,39). 
Limitations. This study has several limitations. This Reg-
istry was designed simply to tabulate data regarding the 
aortic valvuloplasty procedure in a systematic manner. For 
that reason, though prospectively collected, not all baseline 
and follow-up data were available for all variables, compli-
cating analysis of these data. Whenever possible, we have 
completed the actual number of data points from which the 
results were compiled. This limitation is common to registry 
studies such as this and the data should be interpreted in this 
light. 
An additional major limitation is that this is purely an 
observational study and most patients who underwent re-
catheterization did so for clinical reasons. In fact, this study 
represents only 18% of all potentially eligible patients who 
might have been included. This makes generalizations re-
garding the population as a whole tenuous. Fortunately, less 
symptomatic patients were also included because some 
institutions did attempt to recatheterize patients as part of a 
routine protocol. This does allow for some comparative 
observations. 
Though not the case at the 6 month follow-up, the 
baseline variables in those restudied were similar to those 
patients not recatheterized (Table 1). It is important to 
appreciate that 30% of the patients expired before the 6 
month follow-up anniversary. Obviously, the data are biased 
in favor of patients who were both alive and willing to have 
a repeat catheterization procedure performed. Symptoms at 
follow-up were more common in the recatheterization group 
compared with those who were alive and not undergoing 
recatheterization. We do not know the role that procedural 
and other related factors might have in those who are not 
able or willing to return for repeat catheterization. 
Conclusions. Because noninvasive measures for assess-
ing the results of aortic valvuloplasty may differ from inva-
sive measures, recatheterization data are important to char-
acterize the results of aortic valvuloplasty in a systemic 
manner. This study of 95 patients who underwent recathe-
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terization suggest that, despite an early reduction in the 
aortic outflow gradient, a return to the baseline gradient 
occurs in a high percentage of patients even as early as 6 
months. Restenosis appears unrelated to any identifiable 
procedural factor. Because symptoms did not always corre-
late with a return toward the baseline gradient, it is impor-
tant to follow up all patients closely after the procedure. 
Improved definition of the structural characteristics of the 
stenotic aortic valve may result in a better understanding of 
the long-term results from aortic valvuloplasty than will 
modifications in the technique of aortic valvuloplasty itself. 
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